SSSW(SH:688399)2023-10-27 16:00Financial Performance - The company's operating revenue for Q3 2023 was ¥89,817,618.73, a decrease of 91.26% compared to the same period last year[4]. - The net profit attributable to shareholders for Q3 2023 was -¥107,719,636.39, representing a decline of 127.56% year-over-year[4]. - The basic and diluted earnings per share for Q3 2023 were both -¥1.84, reflecting a decrease of 127.59% compared to the same period last year[5][9]. - Net profit for Q3 2023 was a loss of CNY 176,014,301.45, compared to a net profit of CNY 1,624,353,946.03 in Q3 2022[20]. - Total operating revenue for the first three quarters of 2023 was CNY 276,432,339.01, a significant decrease from CNY 4,293,492,259.77 in the same period of 2022[19]. - Total operating costs for the first three quarters of 2023 amounted to CNY 437,980,740.76, down from CNY 2,341,817,019.38 year-over-year[19]. Research and Development - The total R&D investment for Q3 2023 was ¥30,141,555.88, down 51.91% from the previous year, while the R&D investment as a percentage of operating revenue increased by 27.46 percentage points to 33.56%[5][9]. - Research and development expenses for the first three quarters of 2023 were CNY 98,908,502.56, down from CNY 168,206,047.23 in the previous year[19]. Assets and Liabilities - The total assets at the end of the reporting period were ¥4,286,110,440.38, a decrease of 12.37% from the end of the previous year[5]. - The net assets attributable to shareholders decreased by 4.64% to ¥3,602,900,958.39 compared to the end of the previous year[5]. - The company reported a total liability of CNY 683,209,481.99 as of Q3 2023, down from CNY 1,112,849,694.21 in the previous year[19]. - The total equity attributable to shareholders was CNY 3,602,900,958.39, a decrease from CNY 3,778,150,295.65 in the same period last year[17]. Cash Flow - The company reported a cash flow from operating activities of ¥111,883,255.91 for Q3 2023, with a cumulative cash flow of -¥277,430,186.77 year-to-date[5]. - In the first three quarters of 2023, the cash inflow from operating activities was CNY 682,312,507.75, a significant decrease from CNY 4,309,256,328.53 in the same period of 2022, representing a decline of approximately 84.2%[23]. - The net cash flow from operating activities was negative CNY 277,430,186.77, compared to a positive CNY 1,322,234,631.67 in the first three quarters of 2022[23]. - The total cash and cash equivalents at the end of the period were CNY 671,526,103.65, down from CNY 1,103,622,005.97 at the end of the previous year[24]. Shareholder Information - The company reported a total of 15,600,000 shares held by Shaoxing Guokang Biomedical Investment Partnership, making it the largest shareholder[13]. - The top ten unrestricted shareholders collectively hold a significant portion of the company's shares, with the largest individual shareholder, Wang Guoqiang, holding 4,945,200 shares[12]. Market and Product Development - The company experienced a significant decline in revenue primarily due to a sharp drop in income from COVID-related products and services[9]. - The company has not reported any new product developments or market expansion strategies in the current quarter[9]. - The company is focusing on expanding its market presence and enhancing its product offerings, although specific new products or technologies were not detailed in the report[14]. Financial Management - The company's cash flow statement for the first three quarters of 2023 indicates significant changes in cash flow management strategies[22]. - The company recorded a financial expense of CNY -24,150,477.67, compared to CNY -22,546,307.25 in the same period of 2022[19]. - The cash outflow for purchasing goods and services was CNY 376,168,671.51, significantly lower than CNY 1,848,754,998.79 in the previous year[23]. Audit and Reporting - There were no significant changes in the audit opinion type, indicating stability in financial reporting practices[14].